OGN
Organon & Co. · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +8.0% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 112 | -5 | 127.57M | $1.69B | +9 | −13 |
| Q1 2026 | 119 | +3 | 138.29M | $828.86M | +8 | −6 |
| Q4 2025 | 116 | 0 | 159.06M | $1.14B | +2 | −1 |
| Q3 2025 | 19 | +2 | 102.90M | $1.10B | +2 | −1 |
| Q2 2025 | 15 | +2 | 101.45M | $982.02M | +3 | −1 |
| Q1 2025 | 10 | -1 | 22.51M | $334.60M | — | −1 |
| Q4 2024 | 11 | -3 | 17.81M | $265.62M | — | −3 |
| Q3 2024 | 13 | +3 | 12.85M | $245.79M | +4 | −1 |
| Q2 2024 | 10 | — | 11.89M | $246.22M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 4.25M | +2.0% | $81.29M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 4.25M | +2.0% | $81.29M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 2.88M | +67.5% | $55.18M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 2.88M | +67.5% | $55.18M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 2.47M | -28.8% | $47.34M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 2.47M | -28.8% | $47.34M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 2.47M | -28.8% | $47.34M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 8 | Norges Bank ✦ (passive) | 1.50M | +7.0% | $28.69M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Gotham Asset Management ✦ | 801.72K | +12.6% | $15.34M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 239.70K | +343.1% | $4.59M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Bridgewater Associates ✦ | 203.20K | New | $3.89M | 0.0% | New | 1 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 163.23K | +6.7% | $3.12M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 140.49K | New | $2.69M | 0.0% | New | 1 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 140.49K | New | $2.69M | 0.0% | New | 1 | SEC ↗ |
| 15 | Millennium Management ✦ | 91.63K | +39.2% | $1.75M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | Marshall Wace ✦ | 56.48K | New | $1.08M | 0.0% | New | 1 | SEC ↗ |
| 17 | Wellington Management ✦ | 22.86K | New | $437,274 | 0.0% | New | 1 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 20.74K | -83.2% | $396,718 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Bridgewater Associates | $3.89M | 0.0% |
| D. E. Shaw & Co. | $2.69M | 0.0% |
| D. E. Shaw & Co. | $2.69M | 0.0% |
| Marshall Wace | $1.08M | 0.0% |
| Wellington Management | $437,274 | 0.0% |
Exited
| GAMCO Investors | $442,400 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 604 holders, 199.08M shares, $1.18B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.